Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.090
+0.090 (4.50%)
At close: Jun 26, 2026, 4:00 PM EDT
2.040
-0.050 (-2.39%)
After-hours: Jun 26, 2026, 7:50 PM EDT
Daré Bioscience Employees
As of December 31, 2025, Daré Bioscience had 24 total employees, including 21 full-time and 3 part-time employees. The number of employees increased by 1 or 4.35% compared to the previous year.
Employees
24
Change (1Y)
1
Growth (1Y)
4.35%
Revenue / Employee
$48,218
Profits / Employee
-$500,869
Market Cap
31.31M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| Kyntra Bio | 34 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| Lisata Therapeutics | 21 |
| Serina Therapeutics | 16 |
| Barinthus Biotherapeutics | 14 |
| NanoViricides | 7 |
DARE News
- 2 days ago - Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 9 days ago - Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 - GlobeNewsWire
- 16 days ago - Daré Bioscience Transcript: AGM 2026 - Transcripts
- 26 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 26 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 4 weeks ago - Dare Bioscience receives NIH funding award notice to advance DARE-HPV - TheFly
- 4 weeks ago - Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 5 weeks ago - Dare Bioscience initiates DARE-HPV clinical study - TheFly